Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin

Histopathology

Volumn 66, Issue 6, 2015, Pages 898-901

  Rodrigues, Daniel Nava ^a   Hazell, Steve ^b   Miranda, Susana ^a   Crespo, Mateus ^a   Fisher, Cyril ^b   de Bono, Johann S ^a,b   Attard, Gerhardt ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ACINAR CELL CARCINOMA; ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CASE REPORT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATECTOMY; SARCOMATOID CARCINOMA; TISSUE SECTION; ADENOCARCINOMA; CARCINOMA; GENETICS; PATHOLOGY; PROSTATE TUMOR; SECOND CANCER;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASMS, SECOND PRIMARY; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84926651655     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12493     Document Type: Letter

References (8)

1. Leibovici D, Spiess PE, Agarwal PK et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007; 109; 198-204.
2. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R. Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int. 2008; 102; 1369-1374.
3. Hansel DE, Epstein JI. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am. J. Surg. Pathol. 2006; 30; 1316-1321.
4. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 2011; 29; 3659-3668.
5. Scheble VJ, Braun M, Beroukhim R et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol. 2010; 23; 1061-1067.
6. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27; 253-263.
7. Chaux A, Albadine R, Toubaji A et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am. J. Surg. Pathol. 2011; 35; 1014-1020.
8. Pezaro CJ, Omlin A, Lorente D et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 2014; 65; 270-273.